
Veeva Systems Inc.

VEEV (Veeva Systems Inc.) trades at 6.6x EV/Revenue — reasonably priced for a life sciences company with best-in-class gross margins (76%) and moderate growth (+13% YoY). The business is profitable at 29% EBIT margins. Forward PE of 21x.
Adding bonds to a 100% stock portfolio reduces volatility by 30% but only reduces returns by 15% — the free lunch of diversification.
Gold Eagle provides data and AI-generated analysis for informational purposes only. Not investment advice. All data from public sources.
Veeva Systems provides cloud-based software solutions exclusively to the life sciences industry, helping pharmaceutical and biotech companies manage everything from drug development to commercial operations. Their customers include virtually all top 20 pharma companies who rely on Veeva's platforms for clinical trials, regulatory submissions, customer relationship management, and data analytics. They operate a subscription-based model with high switching costs and deep industry expertise.
Veeva delivered 16% revenue growth in FY26 to $3.2B, with FY27 guidance calling for 13% growth driven by Development Cloud expansion and AI capabilities. The company is targeting a potential $1B opportunity through study-by-study CRO partnerships while accelerating RTSM adoption with enterprise standardization. Strong momentum in professional services and Crossix analytics provides additional growth vectors beyond core subscription revenue.
Veeva maintains best-in-class unit economics with 75.5% gross margins and generated $1.4B in non-GAAP operating income for FY26. The company has demonstrated consistent profitability across all business segments, including professional services, while investing heavily in AI capabilities and R&D. Strong cash generation supports continued innovation investments without sacrificing current profitability.
Veeva has built an unassailable moat in life sciences IT through deep regulatory expertise, industry-specific functionality, and high switching costs that competitors struggle to replicate. Unlike horizontal software providers, Veeva's exclusive focus on pharma/biotech creates network effects and specialized capabilities that make displacement extremely difficult. The company's trust-based approach and proven track record of regulatory compliance further strengthen competitive barriers.
Q4 results significantly exceeded expectations with $836M revenue (3.1% beat) and $0.12 EPS beat, capping a stellar FY26 that delivered 16% growth versus 11% initial guidance. Management moved up CRM end-of-support to December 2029 due to strong Vault CRM adoption, while major R&D wins included top 20 pharma standardizations on RTSM and Safety platforms. The AI strategy is gaining tangible traction with clear ROI demonstrations in commercial applications.
Analysts remain constructive on Veeva's long-term prospects despite near-term CRM transition headwinds, with consensus expecting steady double-digit growth and margin expansion. The consistent earnings beats and raised guidance have reinforced confidence in management's execution capabilities. Key debate centers on AI monetization timeline and the pace of Development Cloud adoption offsetting legacy CRM declines.
Veeva represents a rare combination of monopoly-like market position in a growing, regulated industry with emerging AI-driven growth catalysts that should sustain double-digit revenue growth for years to come.
Pre-generated investor questions answered by Claude Opus. Available in the Atlas AI tab.
| '25E | '26E | '27E | '28E | |
|---|---|---|---|---|
| Revenue | $3.2B | $3.6B | $4.0B | $4.5B |
| Growth | — | +13% | +12% | +12% |
| EBITDA | — | $1.5B | $1.6B | $1.9B |
| Growth | — | +12% | +14% | |
| FCF | $1.4B | — | — | — |
| Margin | 44% | — |
AOP Health standardisiert Veeva Industry Cloud for Life Sciences in allen Geschäftsbereichen
Veeva Acquires Ostro, the Leading Brand Engagement Platform for Life Sciences
AOP Health se estandariza en Veeva Industry Cloud para ciencias de la vida en todas sus áreas de negocio
AOP Health Standardizes on Veeva Industry Cloud for Life Sciences Across All Business Areas
Veeva Systems Analyst Says AI Push Keeps Stock Attractive
| — |
| — |
| EPS (PF) | $5.44 | $8.86 | $9.89 | $11.15 |
| Growth | — | +63% | +12% | +13% |
| PF Op Inc | — | $2.0B | $2.2B | $2.6B |